For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

TB-500 vs TB-500 Fragment vs Thymosin Beta-4

Thymosin beta-4 (Tβ4) is a natural 43-amino-acid peptide; TB-500 Fragment is its 7-residue Ac-LKKTETQ segment. “TB-500” is a market name: regulators and doping labs use it for the fragment, while some vendors apply it to full-length Tβ4. Check the COA mass to know which you have.

Side-by-side comparison

NameSequence / lengthApprox. MW (free base)CASHow it shows up on a COA
Thymosin beta-4 (Tβ4)Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (43 aa)~4,963.5 Da (monoisotopic ~4,960.5)77591-33-4MS shows a mass near 4.96 kDa, often as multiply charged ions (e.g. calculated [M+5H]5+ ≈ 993.1, [M+6H]6+ ≈ 827.8)
TB-500 Fragment / Tβ4 17–23Ac-LKKTETQ (7 aa)~889.0 Da (monoisotopic ~888.5)885340-08-9 (free base)MS shows calculated [M+H]+ ≈ 889.5 or [M+2H]2+ ≈ 445.3
Products labeled “TB-500”Either of the above, depending on the supplier~889 Da or ~4,963 DaVariesRead the stated sequence and the observed mass; the name alone does not settle identity
Ac-SDKP (Tβ4 1–4)Ac-SDKP (4 aa)~487.5 Da (monoisotopic ~487.2)127103-11-1 (supplier-listed)MS shows calculated [M+H]+ ≈ 488.2

Masses above are calculated from the sequences for the N-acetylated, C-terminal free acid forms. Salt forms (acetate, TFA) change the formula weight of the bulk powder but not the peptide mass measured by MS. Sequence and residue numbering follow UniProt entry P62328 [4]; the fragment’s CAS number, molecular weight and chemical name follow FDA’s 2026 evaluation [10].

Thymosin beta-4: the natural peptide

Tβ4 is a 43-residue peptide encoded by the TMSB4X gene. The initiator methionine is removed and the N-terminal serine is acetylated, giving the mature chain listed in UniProt P62328 [4]. It belongs to the β-thymosin family, first characterized from thymus extracts, and was later found in many cell types [3].

Its best-characterized intracellular role is binding monomeric (G-) actin. Safer and colleagues showed in 1991 that Tβ4 is identical to Fx, an actin-sequestering peptide isolated from platelets [1]. Mutational mapping by Van Troys et al. located the actin-binding site in two parts: an N-terminal α-helix and a hexapeptide motif at residues 17–22 (LKKTET), with lysine 18 identified as an important contact residue [2]. The critical actin-contacting residues are conserved across the β-thymosin family [2].

What “TB-500” actually refers to

“TB-500” is a common name, not an adopted nonproprietary name [10]. In the analytical and regulatory literature it refers to the short fragment. In 2012, researchers at a WADA-accredited laboratory analyzed a product sold as TB-500 using high-resolution Orbitrap mass spectrometry and identified the N-terminally acetylated 17–23 fragment of Tβ4, Ac-LKKTETQ. They synthesized the fragment and proposed LC-MS/MS methods to detect it in plasma and urine [5]. A separate 2012 study from an equine doping-control laboratory described TB-500 as a synthetic version of an active region of Tβ4 and developed LC-MS methods for horse urine and plasma [6].

FDA’s 2026 evaluation for its Pharmacy Compounding Advisory Committee defines TB-500 as Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (CAS 885340-08-9, MW 889.01 g/mol for the free base) and states that Tβ4 and TB-500 are not the same substance [10].

In the research-chemical market, usage is less consistent. Some products sold as “TB-500” list the full 43-residue Tβ4 sequence and a mass near 4,963 Da, while others list the 7-residue fragment, sometimes sold as “TB-500 Fragment.” Because the same name can describe two molecules that differ in mass by more than 4,000 Da, the sequence and observed mass on the Certificate of Analysis are the only reliable way to know which material a vial contains.

Tβ4 fragments: Ac-LKKTETQ and Ac-SDKP

Ac-LKKTETQ (Tβ4 17–23). This heptapeptide contains the LKKTET actin-binding motif plus the following glutamine, with an added N-terminal acetyl group [5]. It is produced by peptide synthesis, and FDA’s review describes it as a synthetic fragment of Tβ4 [10].

Ac-SDKP (Tβ4 1–4). N-acetyl-seryl-aspartyl-lysyl-proline corresponds to the first four residues of mature Tβ4 and is annotated in UniProt as a hemoregulatory peptide derived from it [4]. It has its own research literature, separate from both Tβ4 and TB-500. For example, Rieger et al. reported in 1993 that Ac-SDKP is a substrate of angiotensin I-converting enzyme (ACE) in human plasma [7]. Ac-SDKP is a different molecule from TB-500 and should not be treated as interchangeable with it.

Research history

Tβ4 has been studied extensively in cell culture and animal models. A 2005 review summarized preclinical work on its actin-sequestering function and on its activity in models of tissue injury [3]. These are preclinical observations and do not establish effects in humans.

Full-length Tβ4 has also entered human clinical trials. RegeneRx Biopharmaceuticals and its partners developed RGN-259, an ophthalmic formulation of synthetic Tβ4. ARISE-3 (NCT03937882) was a Phase 3, randomized, placebo-controlled trial using the controlled adverse environment model [8]. RegeneRx reported in 2021 that ARISE-3 did not meet its primary outcome measures [9]. No Tβ4 product has received FDA approval [10].

The Ac-LKKTETQ fragment has a much smaller literature, concentrated in analytical and doping-control work [5][6]. FDA’s 2026 review stated that it found no published articles in which TB-500 was administered to humans and that potential human safety risks are unknown [10].

Analytical notes: telling them apart

  • Mass spectrometry is the decisive test. Tβ4 has an average mass of about 4,963.5 Da. Ac-LKKTETQ is about 889.0 Da. Ac-SDKP is about 487.5 Da. ESI-MS of Tβ4 usually shows a charge-state envelope that is deconvoluted to the intact mass, while the fragment appears mainly as singly and doubly charged ions.
  • HPLC purity alone cannot confirm identity. A high purity value shows how much of the sample is one main component, not which peptide that component is.
  • Check the stated sequence. A COA should list the full sequence and the N-terminal acetyl group. “Ac-” at the start of the sequence matters: the non-acetylated LKKTETQ is a different compound.
  • Check counterions. FDA lists separate formula weights for TB-500 free base (889.01) and acetate (949.1), and notes that some suppliers use the free-base CAS number for the acetate salt [10].

Regulatory status

  • FDA: Neither Tβ4 nor TB-500 is an FDA-approved drug, and FDA states that TB-500 is not a component of any FDA-approved drug [10]. In its 2026 evaluation, FDA proposed not adding TB-500 (free base or acetate) to the Section 503A bulk drug substances list. At its July 2026 meeting, the advisory committee voted to recommend inclusion. That vote is nonbinding, and at the time of reporting FDA had not made a final decision [11].
  • WADA: The 2026 Prohibited List names “Thymosin-β4 and its derivatives e.g. TB-500” under S2.3, Growth Factors and Growth Factor Modulators, within class S2, which is prohibited at all times [12].

Kalibra products and identity testing

Kalibra supplies TB-500 in 2 mg, 5 mg and 10 mg vials and TB-500 Fragment in 5 mg and 10 mg vials, for laboratory research use only. Each lot’s identity is confirmed by mass spectrometry and reported on its Certificate of Analysis, so researchers can match the observed mass to the sequences above. See how to read a peptide Certificate of Analysis.

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

Not as defined by FDA and the doping-control literature. There, TB-500 is the 7-residue fragment Ac-LKKTETQ (about 889 Da), while Tβ4 is the 43-residue natural peptide (about 4,963 Da) [5][10]. Some vendors use “TB-500” for full-length Tβ4, so check the sequence and mass on the COA.

Is TB-500 approved for human use?

No. Neither TB-500 nor Tβ4 is an FDA-approved drug, and FDA reported finding no published studies in which TB-500 was given to humans [10]. WADA prohibits Tβ4 and its derivatives, including TB-500, at all times under S2.3 [12]. Kalibra’s products are for laboratory research use only.

How can I tell which peptide is in my vial?

Use the mass spectrometry result on the Certificate of Analysis. A mass near 4.96 kDa indicates full-length Tβ4. A mass near 889 Da indicates Ac-LKKTETQ. A mass near 487 Da indicates Ac-SDKP. HPLC purity alone does not confirm identity.

Is Ac-SDKP the same as TB-500 Fragment?

No. Ac-SDKP is residues 1–4 of Tβ4, while TB-500 Fragment is residues 17–23 (Ac-LKKTETQ). They share a parent protein but are different molecules with separate research literatures [4][7].

References

  1. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029–4032. PubMed 1999398
  2. Van Troys M, Dewitte D, Goethals M, Carlier MF, Vandekerckhove J, Ampe C. The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO J. 1996;15(2):201–210. PubMed 8617195
  3. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429. PubMed 16099219
  4. UniProt Consortium. P62328 (TYB4_HUMAN): Thymosin beta-4. UniProtKB. uniprot.org/uniprotkb/P62328
  5. Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733–738. PubMed 22962027
  6. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. PubMed 23084823
  7. Rieger KJ, Saez-Servent N, Papet MP, et al. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline. Biochem J. 1993;296:373–378. PubMed 8257427
  8. ReGenTree, LLC. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 (NCT03937882). ClinicalTrials.gov. clinicaltrials.gov/study/NCT03937882
  9. ARISE-3 Dry Eye Trial Does Not Meet Primary Outcome Measures. American Pharmaceutical Review. March 23, 2021. americanpharmaceuticalreview.com
  10. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23–24, 2026: Evaluation of TB-500-related Bulk Drug Substances. FDA, 2026. fda.gov/media/193349
  11. FDA panel backs 6 peptides for compounding. AJMC. July 31, 2026. ajmc.com
  12. World Anti-Doping Agency. 2026 Prohibited List. wada-ama.org/en/prohibited-list

For Research Use Only. Not for human or veterinary use. Not for use in diagnostic or therapeutic procedures. This guide summarizes published literature for laboratory reference and is not medical advice.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top